OsteoApp.ai’s proprietary, FDA cleared cloud-based Software as a Service (SaaS) screening service enables simple measurement of bone mineral density (BMD) and early detection of osteoporosis by rapid automated analysis of standard X-rays. This method requires no additional equipment expenditures, minimizes workflow disruption, and yields immediate and accurate clinical results. In addition, the unique retrospective screening capability, when combined with automated, real time clinical screening, makes OsteoApp.ai a powerful clinical tool.
OsteoApp.ai is a technology spin off of Sectra AB, publicly traded European digital imaging company that provides an FDA cleared, automated osteoporosis screening technology clinically shown to identify patients at high risk for costly hip1 and vertebral fractures.
OsteoApp and was formed in part to deploy to the US market this clinically proven technology while developing next generation screening capabilities with exclusively licensed artificial intelligence technologies developed by the University of Rochester.